Composition and method for the treatment of eye disease
Embodiments of the invention disclosed herein relate to compositions comprising carnosine and N-acetyl-histitidine in a pharmaceutically acceptable carrier. Other embodiments disclosed herein relate to preventing and/or ameliorating one or more symptoms associated with an eye disease such as dry eye syndrome, cataracts of the eye and nuclear sclerosis of the eye lens. Kits for preventing and/or ameliorating one or more symptoms associated with an eye disease by administering a pharmaceutical composition comprising N-acetyl-histidine are also disclosed.
1. A pharmaceutical composition comprising β-alanyl-L-histidine (carnosine) and N-acetyl-histidine in a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , further comprising carboxymethylcellulose.
3. The pharmaceutical composition of claim 1 , wherein both carnosine and N-acetyl-histidine are present in a concentration from about 0.1% (w/v) to about 30% (w/v).
4. The pharmaceutical composition of claim 1 , wherein said carnosine is present in a concentration of about 1% (w/v), N-acetyl-histidine is present in a concentration of about 1.2% (w/v), and said carboxymethylcellulose is present in a concentration of about 0.5% (w/v).
5. The pharmaceutical composition of claim 1 , wherein said carnosine is present in a concentration of about 6% (w/v), N-acetyl-histidine is present in a concentration of about 7.2% (w/v), and said carboxymethylcellulose is present in a concentration of about 1% (w/v).
6. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier is water.
7. The pharmaceutical composition of claim 6 , wherein said water is sterile.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier is a sodium chloride solution.
9. The pharmaceutical composition of claim 8 , wherein said sodium chloride solution is present in a concentration of about 0.9% (w/v).
10. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier is an ointment.
11. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier is a gel.
12. A kit for treating an eye disease, said kit comprising a container comprising a formulation of carnosine and N-acetyl-histidine in a pharmaceutically acceptable carrier and instructions for administering said formulation such that said administration treats said eye disease.
13. The kit of claim 12 , wherein both carnosine and N-acetyl-histidine are present in a concentration from about 0.1% (w/v) to about 30% (w/v).
14. The kit of claim 12 , wherein said N-acetyl-L-histidine is present in a concentration from about 1% (w/v) to about 15% (w/v).
15. The kit of claim 12 , wherein the formulation further comprises carboxymethylcellulose.
16. The kit of claim 12 , wherein said container is a dropper.
17. The kit of claim 12 , wherein said container is a tube.